Vanguard Fiduciary Trust
LIMN

Vanguard Fiduciary Trust’s Liminatus Pharma LIMN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53K Hold
22,984
– – ﹤0.01% 4072
2026
Q1 		$3.95K Buy
+22,984
New +$12.3K ﹤0.01% 4038

Other funds holding LIMN

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Fiduciary Trust's LIMN Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Liminatus Pharma (LIMN) position steady in Q2 2026 at 22,984 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #4072.

Vanguard Fiduciary Trust first reported a position in LIMN in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.95K in Q1 2026. 13 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Vanguard Fiduciary Trust held 22,984 shares of Liminatus Pharma worth $2.53K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Liminatus Pharma share count unchanged in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4072 holding.
  • Vanguard Fiduciary Trust first reported a position in Liminatus Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Liminatus Pharma position peaked at $3.95K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.